Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center + Summit Therapeutics
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Safety and adverse events (AEs)
Time frame: Through study completion; an average of 1 year.
Eligibility Criteria
Inclusion Criteria: * Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures. * Age ≥18 years. * Has locally advanced surgically non-appropriate (unresectable and/or metastatic) cSCC (Cohort 1).. * Has metastatic CRPC (Cohort 2): * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology. * Documented prostate cancer progression as documented by PSA progression according to PCWG3 criteria. * Surgically or medically castrated, with serum testosterone level \<50 ng/dL. * Refractory or naïve to anti-PD-1 therapy (Cohort 1). There is no limit on the number of prior lines of therapy. NOTE: Detailed information regarding duration of prior anti-PD-1 therapy and the extent of progression at the time of anti-PD-1 therapy discontinuation will be collected. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1)…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →